Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volixibat - Mirum Pharmaceuticals

Next Previous
Drug Profile

Volixibat - Mirum Pharmaceuticals

Alternative Names: LUM-002; SAR-548304; SHP-626; Volixibat - Takeda; Volixibat potassium

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Mirum Pharmaceuticals; Sanofi; Shire
  • Class Anti-inflammatories; Antihyperlipidaemics; Benzothiepins; Hepatoprotectants; Urea compounds
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary biliary cirrhosis
  • Phase II Intrahepatic cholestasis; Primary sclerosing cholangitis
  • No development reported Cholestasis
  • Discontinued Hypercholesterolaemia; Non-alcoholic steatohepatitis

Most Recent Events

  • 12 May 2025 Updated efficacy data from the phase IIb VANTAGE trial in Primary biliary cirrhosis released by Mirum Pharmaceuticals
  • 29 Apr 2025 Updated efficacy and adverse events data from the phase IIb VANTAGE trial in Primary biliary cirrhosis released by Mirum Pharmaceuticals
  • 15 Nov 2024 Efficacy and adverse event data from the clinical trial in Primary biliary cholangitis presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases 2024 (AASLD-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top